Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6221438 | 1.00 | TLR8 (0.48) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL943825 | 0.95 | TLR8 (0.47) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL7989266 | 0.94 | TLR8 (0.45) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL12264373 | 0.94 | TLR8 (0.47) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL29263655 | 0.94 | TLR8 (0.47) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL18751236 | 0.94 | TLR8 (0.47) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| Trifluoroacetic Acid SCHEMBL27848401 | 0.92 | TLR8 (0.43) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL13496025 | 0.90 | TLR8 (0.43) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL12644325 | 0.90 | USP2 (0.50) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL46682 | 0.90 | USP2 (0.50) | TLR8USP2SMN1; SMN2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112142733-A | Synthetic route of pan FGFR covalent inhibitor PRN1371 | 湖南师范大学 | 2020-12-29 | — | — | CN | claimed |
| US-20260115297-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL MED MOUNT SINAI (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115187-A1 | TRICYCLIC SKELETON COMPOUND AND USE THEREOF IN PREPARATION OF ANTITUMOR DRUG | ZHONGSHAN HOSPITAL, FUDAN UNIVERSITY (CN) | 2026-04-30 | — | — | US | disclosed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2026-03-24 | — | — | US | disclosed |
| US-12465648-B2 | Heterobifunctional compounds as degraders of HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4620949-A1 | ACKR3 MODULATORS FOR CARDIOVASCULAR OR ANTIPLATELET THERAPY | Eberhard Karls Universität Tübingen (Medizinische Fakultät) (DE) | 2025-09-24 | — | — | EP | disclosed |
| EP-4608454-A1 | SELF-HYDROLYZING MALEIMIDES FOR BIOCONJUGATION | Eli Lilly and Company (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| WO-2007092095-A2 | [4-(BENZO [B] THI0PHEN-2-YL) PYRIMIDIN-2YL] -AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES. | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1778670-A2 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM Pharma A/S (DK) | 2007-05-02 | — | — | EP | disclosed |
| EP-1737463-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| US-7132295-B2 | Isotopically coded affinity markers 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2006-11-07 | — | — | US | disclosed |
| WO-2006071035-A1 | NOVEL ([1,3]THIAZOLO[5,4-B]PYRIDIN-2-YL)-2-CARBOXAMIDE DERIVATIVES | LG LIFE SCIENCES, LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006010446-A2 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005060970-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| US-20050049406-A1 | Isotopically coded affinity markers 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-03 | — | — | US | disclosed |
| EP-1446665-A2 | ISOTOPICALLY CODED AFFINITY MARKERS 3 | Bayer HealthCare AG (DE) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003040288-A2 | ISOTOPICALLY CODED AFFINITY MARKERS 3 | BAYER HEALTHCARE AG (DE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | TYRO3, TH, SRMS | TLR8 264/4885USP2 4057/4885SMN1; SMN2 1810/4885 |
| US-12465648-B2 | Heterobifunctional compounds as degraders of HPK1 | HIPK1, MCL1, HYPK | TLR8 4145/4885USP2 331/4885SMN1; SMN2 3222/4885 |
| US-20260115187-A1 | TRICYCLIC SKELETON COMPOUND AND USE THEREOF IN PREPARATION OF ANTITUMOR DRUG | HCCS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1 | TLR8 4519/4885USP2 4607/4885SMN1; SMN2 2240/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | TLR8 4512/4885USP2 1066/4885SMN1; SMN2 744/4885 |
| US-20260115297-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | TTK, ITK, CLK1 | TLR8 3906/4885USP2 337/4885SMN1; SMN2 4005/4885 |
| US-20050049406-A1 | Isotopically coded affinity markers 3 | IGFBP3, FABP3, LGALS3BP | TLR8 4869/4885USP2 1633/4885SMN1; SMN2 2814/4885 |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCR2, CXCR1 | TLR8 366/4885USP2 2703/4885SMN1; SMN2 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.